Clipboard, Search History, and several other advanced features are temporarily unavailable. Skip to main page content
The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search: Search Advanced Clipboard User Guide Save Email Send to
Clipboard
My Bibliography
Collections
Citation manager
Display options Display options Format Abstract PubMed PMID
Subject: 1 selected item: 33020644 - PubMed To: From: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel
Add to Collections
Create a new collection
Add to an existing collection
Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Please try again Add Cancel
Add to My Bibliography
My Bibliography
Unable to load your delegates due to an error Please try again Add Cancel
Your saved search
Name of saved search: Search terms: Test search terms Would you like email updates of new search results? Saved Search Alert Radio Buttons
Yes
No
Email: (change) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel
Create a file for external citation management software
Create file Cancel
Your RSS Feed
Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy
Full text links
Nature Publishing Group Free PMC article Full text links
Actions
CiteCollectionsAdd to Collections
Create a new collection
Add to an existing collection
Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an errorPlease try again Add Cancel Display options Display options Format AbstractPubMedPMID
Share
Permalink Copy
Page navigation
Title & authors
Abstract
Figures
Comment in
Similar articles
Cited by
References
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Title & authors Abstract Figures Comment in Similar articles Cited by References Publication types MeSH terms Substances Related information Grants and funding LinkOut - more resources Full text links CiteDisplay options Display options Format AbstractPubMedPMID
Abstract
Autologous chimeric antigen receptor (CAR) T cell therapies targeting CD19 have high efficacy in large B cell lymphomas (LBCLs), but long-term remissions are observed in less than half of patients, and treatment-associated adverse events, such as immune effector cell-associated neurotoxicity syndrome (ICANS), are a clinical challenge. We performed single-cell RNA sequencing with capture-based cell identification on autologous axicabtagene ciloleucel (axi-cel) anti-CD19 CAR T cell infusion products to identify transcriptomic features associated with efficacy and toxicity in 24 patients with LBCL. Patients who achieved a complete response by positron emission tomography/computed tomography at their 3-month follow-up had three-fold higher frequencies of CD8 T cells expressing memory signatures than patients with partial response or progressive disease. Molecular response measured by cell-free DNA sequencing at day 7 after infusion was significantly associated with clinical response (P = 0.008), and a signature of CD8 T cell exhaustion was associated (q = 2.8 × 10-149) with a poor molecular response. Furthermore, a rare cell population with monocyte-like transcriptional features was associated (P = 0.0002) with high-grade ICANS. Our results suggest that heterogeneity in the cellular and molecular features of CAR T cell infusion products contributes to variation in efficacy and toxicity after axi-cel therapy in LBCL, and that day 7 molecular response might serve as an early predictor of CAR T cell efficacy.
PubMed Disclaimer
Figures
Extended Data 1:
Heatmap showing the top…
Extended Data 1:
Heatmap showing the top 50 signature genes of each cluster and putative…
Extended Data 1: Heatmap showing the top 50 signature genes of each cluster and putative assignments to cell types according to canonical marker genes.
Extended Data 2:. Increased sequencing saturation and…
Extended Data 2:. Increased sequencing saturation and marker gene detection rate by CapID.
a) Sub-sampling… Extended Data 2:. Increased sequencing saturation and marker gene detection rate by CapID. a) Sub-sampling of reads from a single CAR T infusion product with 600 million reads for whole transcriptome and 20 million reads for CapID, showing the saturation (flattening of curve) for CapID (orange) at ~10 million reads, for 10X whole transcriptome sequencing (blue) at ~400M reads, and the effect of supplementing whole transcriptome data with 10 million reads of CapID data (green). b) Density plots from the entire dataset show the reduced number of cells with UMI counts of zero and increased signal-to-noise ratio for CapID sequencing compared to 10X whole transcriptome sequencing. The 10X whole transcriptome sequencing in this study were performed to an average of 73,521 reads per cell, vastly exceeding the minimum of 20,000 reads per cell recommended by 10X.
Extended Data 3:. Correlation of cell frequencies…
Extended Data 3:. Correlation of cell frequencies measured by scRNA-seq and flow cytometry.
Correlations are…
Extended Data 3:. Correlation of cell frequencies measured by scRNA-seq and flow cytometry. Correlations are shown for 16 patients that had sufficient cells for flow cytometry (a), compared to the fractions measured using traditional 10X data (b) or CapID+ (c). All comparisons showed a significant correlation with Pearson’s correlation 2-tailed P-value < 0.001.
Extended Data 4:. Volcano plots of differentially…
Extended Data 4:. Volcano plots of differentially expressed genes between CAR-positive and CAR-negative CD8 and…
Extended Data 4:. Volcano plots of differentially expressed genes between CAR-positive and CAR-negative CD8 and CD4 T-cells. Q-values were calculated with a two-sided Wilcoxon rank sum test with Bonferonni correction.
Extended Data 5:. Variant allele fractions of…
Extended Data 5:. Variant allele fractions of somatic variants detected by cfDNA sequencing.
a-b) Comparison… Extended Data 5:. Variant allele fractions of somatic variants detected by cfDNA sequencing. a-b) Comparison of the average VAF of mutations at day 0 (a) and the number of calibrated mutations (b) between clinical response groups. P values were calculated by a two-sided Student’s t-test. c) Raw variant allele frequencies for each patient are shown for >5FMR (above) and <5FMR (below) groups. Lines are colored by clinical response as in figure 4a. The grey dashed line represents the 5-fold reduction threshold for each patient.
Extended Data 6:. T-cell clonotypic diversity in…
Extended Data 6:. T-cell clonotypic diversity in patients grouped by clinical and molecular response.
a)… Extended Data 6:. T-cell clonotypic diversity in patients grouped by clinical and molecular response. a) The frequency of the top 10 clonotypes for each patient among all cells (above), CD4 T-cells (middle) and CD8 T-cells (below). Box, median +/− interquartile range. Whiskers, minimum and maximum. P-values calculated by a two-sided Wilcoxon rank sum test with Benjamini-Hochberg correction. b) Shannon’s clonality score for patients grouped by clinical or molecular response, shown for all cells (above), CD4 T-cells (middle) and CD8 T-cells (below). CR, n=9. PR/PD, n=14. >5FMR, n=8. <5FMR, n=9. Box, median +/− interquartile range. Whiskers, minimum and maximum. P-values calculated by a two-sided Wilcoxon rank sum test with Benjamini-Hochberg correction.
Extended Data 7:. Analysis of association between…
Extended Data 7:. Analysis of association between molecular features of CAR T-cell infusion products and…
Extended Data 7:. Analysis of association between molecular features of CAR T-cell infusion products and the development of high-grade cytokine release syndrome (CRS). a) Comparison of functional states between patients with grade 0–2 and grade 3–4 identified reduced frequencies of exhausted CD8 T-cells and increased frequencies of exhausted CD4 T-cells to be associated with the development of high-grade CRS. Q-values were calculated by a two-sided Fisher exact test with a Benjamini-Hochberg correction. b-c) Heatmaps show differentially expressed genes between CD4 T-cells (b) and CD8 T-cells. (c) from the infusion products of patients with grade 0–2 CRS versus those that developed grade 3–4 CRS. The CD69 gene shows higher expression and the CCL3 and CLL4 genes show lower expression on both CD4 and CD8 T-cells from the CAR T-cell infusion products of patients that developed high grade CRS. All differentially expressed genes are shown in Supplementary Tables 10 and 11.
Extended Data 8:. Percentage of CAR-positive cells…
Extended Data 8:. Percentage of CAR-positive cells in patients with grade 0–2 vs grade 3–4…
Extended Data 8:. Percentage of CAR-positive cells in patients with grade 0–2 vs grade 3–4 ICANS. Grade 0–2 ICANS, n=22. Grade 3–4 ICANS, n=18. Box, median +/− interquartile range. Whiskers, minimum and maximum. P-values calculated by a two-sided Wilcoxon rank-sum test.
Extended Data 9:. Cytokine levels in serum…
Extended Data 9:. Cytokine levels in serum between patients with IACs and those without IACs.
Extended Data 9:. Cytokine levels in serum between patients with IACs and those without IACs. Significance level was tested with Mann-Whitney U test. FDR q-value was calculated for multiple testing correction.
Extended Data 10:. Quantification of the ICANS-associated…
Extended Data 10:. Quantification of the ICANS-associated cells (IACs) signature by scGSVA in CAR T-cell…
Extended Data 10:. Quantification of the ICANS-associated cells (IACs) signature by scGSVA in CAR T-cell infusion products. a) A stringent threshold was set to ensure high confidence classification of IACs by scGSVA analysis of the 109 signature genes measured by CapID, as shown for the cells that were originally identified as IACs by unsupervised clustering of 10X whole-transcriptome data in figure 4a. b) The distribution of scGSVA scores shows a clear difference between infusion products from patients with grade 0–2 ICANS vs patients with grade 3–4 ICANS. The threshold for classification of cells as IACs (scGSVA score >1.5) is shown.
Figure 1:. Single cell analysis of standard…
Figure 1:. Single cell analysis of standard of care (SOC) CAR T-cell infusion products.
A…
Figure 1:. Single cell analysis of standard of care (SOC) CAR T-cell infusion products. A schematic overview of the experimental design and bioinformatics flow for scRNA-seq analysis of 137,276 residual cells from CAR T-cell infusion products of 24 LBCL patients. Our approach incorporated single cell transcriptome profiling of CAR T-cell infusion products boosted by CapID+, correlation of single cell functional states and gene expression signatures with efficacy assessed by positron emission tomography/computed tomography (PET/CT) and by cfDNA sequencing, and with toxicity assessed by clinical grading.
Figure 2:. Single cell analysis of standard…
Figure 2:. Single cell analysis of standard of care (SOC) CAR T-cell infusion products.
a)… Figure 2:. Single cell analysis of standard of care (SOC) CAR T-cell infusion products. a) An overview of the 133,405 cells that passed quality control (QC) for subsequent analyses in this study. Cells are color coded by the corresponding patient origin (sample ID) in the tSNE plot and a bar graph showing the number of cells per patient that passed QC. b) Cells are color coded by tSNE cluster number and a bar graph showing the distribution of cells from each patient among clusters. c) Individually scaled density plots show the normalized expression for the CAR, CD4 and CD8B transcripts in 10X scRNA-seq data and CapID hybrid capture sequencing data derived from the same scRNAseq libraries. Histogram overlays with identical scaling showing the relative fraction of cells with zero counts are shown in Extended Data 2b. d) The tSNE overview and bar graph summary of the cells identified as being CAR-positive (left), CD4 T-cells (middle) and CD8 T-cells (right) using 10X scRNA-seq data and those rescued by CapID+.
Figure 3:. Molecular phenotypes of CAR T-cell…
Figure 3:. Molecular phenotypes of CAR T-cell infusion products associated with response determined by PET/CT.
Figure 3:. Molecular phenotypes of CAR T-cell infusion products associated with response determined by PET/CT. a) Cell types and functional states that were significantly more frequent in CAR T-cell products from patients with continued CR at 3 months (blue) or those from patients with PR/PD (red). Q-values were calculated by a two-sided Fisher exact test with a Benjamini-Hochberg correction. b) Heatmap of four CD8+ T cell clusters (C1-C4) generated from unsupervised clustering of genes that were differentially expressed in CD8 T-cells from the infusion products of patients with CR compared to those from patients with PR/PD. A color-coded track shows the cells that originated from infusion products of CR patients (blue: CR) and the percentage of these cells within each cluster labelled at the top. Additional tracks show the scGSVA scores of CD8 dysfunction and CD8 memory signatures, respectively, and the inferred cell cycle status. The percentage of cells that originated from infusion products of CR patients is significantly different between clusters (One-way ANOVA p < 2.2×10−16). The corresponding sample origins are labeled at the bottom, colored as per Figure 2a. c) Violin plots show the scGSVA scores of cells from each the four clusters in 2b. C1, n=26,917 cells. C2, n=9,047 cells. C3, n=10,113 cells. C4, n=6,440 cells. Box, median +/− interquartile range. Whiskers, 1.5X interquartile range. Pairwise comparisons were performed using a two-sided Wilcoxon rank-sum test with a Benjamini-Hochberg correction. d) Scatter plots of CCR7+CD27+ CD8 T-cells measured by CapID in the infusion products of patients who achieved CR compared to those who had PR/PD (Two-sided Fisher exact test p<2.2× 10−16). e) Gene sets that are significantly positively (+) or negatively (−) associated with CR in CD8 (above) or CD4 (below) T-cells. For each pathway, a heatmap of the single cell GSVA scores are shown, with % of cells originated from infusion products of CR patients annotated on the top. The origin of the gene set is shown in brackets (B, biocarta; R, reactome; K, KEGG; P, PID). f) A heatmap of five CD4+ T cell clusters (C1-C5) determined by unsupervised clustering of genes that were differentially expressed in CD4 T-cells from infusion products of patients with CR compared to those from patients with PR/PD. The percentage of cells that originated from infusion products of CR patients is shown in a track at the top and is significantly different between clusters (One-way ANOVA p < 2.2×10−16). Cells are annotated by inferred cell cycle state and sample origin as in panel b.
Figure 4:. Association between early molecular response…
Figure 4:. Association between early molecular response measured by cfDNA sequencing and clinical response measured…
Figure 4:. Association between early molecular response measured by cfDNA sequencing and clinical response measured by PET/CT. a) Molecular response measured by deep targeted cfDNA sequencing over the first month following infusion. Variant allele fraction (VAF) for each patient (n = 17) are normalized to the infusion day time point (day 0) and lines are colored according to response assessed by PET/CT at their 3-month follow-up or prior disease progression. b) Fold change in molecular disease burden at the day 7 time point relative the day 0 time point is shown for each patient, with bars colored by clinical response determined by PET/CT at their 3 month follow-up. The fold reduction of molecular disease burden was significantly associated with clinical response at 3 months (two-sided Wilcoxon rank-sum P = 0.008). The 16 patients with evaluable response were split into two groups according to whether they achieved >5-fold molecular response (>5FMR) or had <5-fold molecular response (<5FMR).
Figure 5:. Association between CD8 T-cell exhaustion…
Figure 5:. Association between CD8 T-cell exhaustion markers and early molecular response.
a) Cell types… Figure 5:. Association between CD8 T-cell exhaustion markers and early molecular response. a) Cell types and functional states associated with >5-fold molecular response at day 7 (>5FMR, blue) or failure to achieve 5-fold molecular response at day 7 (<5FMR, red). Q-values were calculated by a two-sided Fisher exact test with a Benjamini-Hochberg correction. b) The percentage of cells expressing co-inhibitory molecules utilized in the classification of exhausted CD8 T-cells, and the percentage of cells co-expressing LAG3 and TIM3, is shown for cells from patients with >5FMR (turquoise) compared to those from patients with <5FMR (red). c) Scatter plots show the expression of LAG3 and TIM3 in cells from patients who achieved >5FMR (left, blue) compared to those from patients with <5FMR (right, red). Each point represents a single cell and the proportion of cells at each state is labelled on the plot. Expression levels are normalized UMI counts from CapID sequencing, with normalized UMI counts >2 defined as positive expression. d) The percentage of cells from each TCR clonotype (identified from single cell TCR sequencing) co-expressing LAG3 and TIM3 are shown and data are compared between clonotypes within infusion products of patients with >5FMR (above, blue) and those from patients with <5FMR (below, red). The size of each point indicates the clonal fraction of each clonotype within each infusion product. >5FMR; n=72 clonotypes from 8 patients. <5FMR; n=196 clonotypes from 9 patients. Boxes, median +/− the interquartile range; whiskers, 1.5x interquartile range. P value was calculated by two-sided Wilcoxon rank-sum test. e) Transcripts were measured in 38,601 cells from fresh core needle biopsies of 9 rrLBCL tumors by CapID; 5 patients progressing following chemo-immunotherapy or targeted therapy (CAR T naïve) and 4 patients progressing following axi-cel CAR T-cell therapy (post-CAR T). The expression of TIM3 and LAG3 was quantified by CapID within CD8 T-cells in CAR T naïve and post-CAR T tumors, and within CD8 T-cells expressing the CAR transcript in post-CAR T tumors. The fraction of single- and double-positive cells annotated.
Figure 6:. ICANS-associated cells in CD19 CAR…
Figure 6:. ICANS-associated cells in CD19 CAR T-cell infusion products.
a) Clusters are shown for… Figure 6:. ICANS-associated cells in CD19 CAR T-cell infusion products. a) Clusters are shown for 10X transcriptome data of 24 patients in a tSNE plot, colored by the significance of their association with ICANS. The significant cluster of ICANs-associated cells (IACs) is circled. P-values were calculated using a two-sided Wilcoxon rank-sum test. b) Genes that are most highly expressed in cells from the IACs cluster compared to cells from other clusters are shown in a heatmap. Expression of additional T-cell markers, T-cell receptor (TCR) gene rearrangements and the CAR transcript are shown in tracks at the top. c) The expression of representative IACs markers, T-cell markers and canonical monocyte markers are shown for each cluster. The size of bubbles is relative to the percentage of cells within a cluster that express a given gene, and the color is relative to the mean expression of a given gene within each cluster. d) Density plots show the cellular distribution of transcript abundance of IACs marker genes in cells from the IAC cluster compared to cells from other clusters, determined by 10X transcriptome data. e) Single sample gene set enrichment (ssGSEA) values are shown for the IACs signature genes within gene expression data from purified populations of normal hematopoietic cell subsets, with increasing scores representing higher expression of the gene set. Myeloid lineage subsets [left, peach] have a significantly higher expression of genes that are characteristic of the IACs cluster compared to lymphoid lineage cells (Two-sided Wilcoxon rank-sum test, p<2.2×10−16). The highest expression of the IACs signature genes observed in monocytes. N=6 for all cell types except for basophils (n=4), myeloid DCs (n=5), non-classical monocytes (n=5), and memory CD8 T-cells (n=5). Boxes, median +/− the interquartile range; whiskers, 1.5x interquartile range. f) The cellular proportion of IACs determined by measurement of signature genes by CapID the infusion products of 269,164 single cells from 40 patients’ CAR T-cell infusion products (24 patient discovery cohort, 16 patient validation cohort [bold sample ID]) is shown. The samples are grouped according to patients with grade 3–4 ICANS (n=18, orange) compared to grade 0–2 ICANS (n=22, blue). Box, median +/− interquartile range. Whiskers, 1.5x interquartile range. P value was calculated by a two-sided Wilcoxon rank-sum test. All figures (16) See this image and copyright information in PMC
Using single-cell analysis to predict CAR T cell outcomes. Ramakrishna S, Shah NN.Ramakrishna S, et al.Nat Med. 2020 Dec;26(12):1813-1814. doi: 10.1038/s41591-020-01157-w.Nat Med. 2020.PMID: 33230341No abstract available.
Similar articles
Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma. Dong N, Rubio Lopes-Garcia L, Viñal D, Bachmeier C, Shah BD, Nishihori T, Khimani F, Davila ML, Lazaryan A, Pinilla-Ibarz J, Locke FL, Jain MD, Chavez JC.Dong N, et al.Transplant Cell Ther. 2023 Jun;29(6):349.e1-349.e8. doi: 10.1016/j.jtct.2023.02.021. Epub 2023 Mar 5.Transplant Cell Ther. 2023.PMID: 36878427
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. Sesques P, Kirkwood AA, Kwon M, Rejeski K, Jain MD, Di Blasi R, Brisou G, Gros FX, le Bras F, Bories P, Choquet S, Rubio MT, Iacoboni G, O'Reilly M, Casasnovas RO, Bay JO, Mohty M, Joris M, Abraham J, Castilla Llorente C, Loschi M, Carras S, Chauchet A, La Rochelle LD, Hermine O, Guidez S, Cony-Makhoul P, Fogarty P, Le Gouill S, Morschhauser F, Gastinne T, Cartron G, Subklewe M, Locke FL, Sanderson R, Barba P, Houot R, Bachy E.Sesques P, et al.J Hematol Oncol. 2024 Aug 6;17(1):61. doi: 10.1186/s13045-024-01579-w.J Hematol Oncol. 2024.PMID: 39107847Free PMC article.
Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas. Riedell PA, Hwang WT, Nastoupil LJ, Pennisi M, McGuirk JP, Maziarz RT, Bachanova V, Oluwole OO, Brower J, Flores OA, Ahmed N, Schachter L, Bharucha K, Dholaria BR, Schuster SJ, Perales MA, Bishop MR, Porter DL.Riedell PA, et al.Transplant Cell Ther. 2022 Oct;28(10):669-676. doi: 10.1016/j.jtct.2022.07.011. Epub 2022 Jul 16.Transplant Cell Ther. 2022.PMID: 35850429Free PMC article.
Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Holtzman NG, Xie H, Bentzen S, Kesari V, Bukhari A, El Chaer F, Lutfi F, Siglin J, Hutnick E, Gahres N, Ruehle K, Ahmad H, Shanholtz C, Kocoglu MH, Badros AZ, Yared JA, Hardy NM, Rapoport AP, Dahiya S.Holtzman NG, et al.Neuro Oncol. 2021 Jan 30;23(1):112-121. doi: 10.1093/neuonc/noaa183.Neuro Oncol. 2021.PMID: 32750704Free PMC article.Review.
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Chow VA, Shadman M, Gopal AK.Chow VA, et al.Blood. 2018 Aug 23;132(8):777-781. doi: 10.1182/blood-2018-04-839217. Epub 2018 Jun 18.Blood. 2018.PMID: 29914976Free PMC article.Review.
See all similar articles
Cited by
A novel mitochondrial pyruvate carrier inhibitor drives stem cell-like memory CAR T cell generation and enhances antitumor efficacy. Wenes M, Lepez A, Arinkin V, Maundrell K, Barabas O, Simonetta F, Dutoit V, Romero P, Martinou JC, Migliorini D.Wenes M, et al.Mol Ther Oncol. 2024 Oct 18;32(4):200897. doi: 10.1016/j.omton.2024.200897. eCollection 2024 Dec 19.Mol Ther Oncol. 2024.PMID: 39559715Free PMC article.
A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors? Andrea AE, Chiron A, Sarrabayrouse G, Bessoles S, Hacein-Bey-Abina S.Andrea AE, et al.Front Immunol. 2024 Oct 4;15:1459818. doi: 10.3389/fimmu.2024.1459818. eCollection 2024.Front Immunol. 2024.PMID: 39430751Free PMC article.Review.
New horizons in our understanding of precursor multiple myeloma and early interception. Cordas Dos Santos DM, Toenges R, Bertamini L, Alberge JB, Ghobrial IM.Cordas Dos Santos DM, et al.Nat Rev Cancer. 2024 Dec;24(12):867-886. doi: 10.1038/s41568-024-00755-x. Epub 2024 Oct 16.Nat Rev Cancer. 2024.PMID: 39414947Review.
Advancement and Challenges in Monitoring of CAR-T Cell Therapy: A Comprehensive Review of Parameters and Markers in Hematological Malignancies. Ploch W, Sadowski K, Olejarz W, Basak GW.Ploch W, et al.Cancers (Basel). 2024 Sep 29;16(19):3339. doi: 10.3390/cancers16193339.Cancers (Basel). 2024.PMID: 39409959Free PMC article.Review.
BRD4 inhibitor reduces exhaustion and blocks terminal differentiation in CAR-T cells by modulating BATF and EGR1. Sui S, Zhong M, Zhong S, Peng X, Mao L, Chen C, Zeng C, Luo OJ, Li Y.Sui S, et al.Biomark Res. 2024 Oct 15;12(1):124. doi: 10.1186/s40364-024-00667-w.Biomark Res. 2024.PMID: 39407311Free PMC article.
See all "Cited by" articles
References
Locke FL et al.Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol 20, 31–42, doi:10.1016/S1470-2045(18)30864-7 (2019). - DOI - PMC - PubMed
Schuster SJ et al.Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. The New England journal of medicine 380, 45–56, doi:10.1056/NEJMoa1804980 (2019). - DOI - PubMed
Shah NN & Fry TJ Mechanisms of resistance to CAR T cell therapy. Nature reviews. Clinical oncology 16, 372–385, doi:10.1038/s41571-019-0184-6 (2019). - DOI - PMC - PubMed
Neelapu SS et al.Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. The New England journal of medicine 377, 2531–2544, doi:10.1056/NEJMoa1707447 (2017). - DOI - PMC - PubMed
Mueller KT et al.Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research 24, 6175–6184, doi:10.1158/1078-0432.CCR-18-0758 (2018). - DOI - PMC - PubMed
Show all 44 references
Methods-only References
Fraietta JA et al.Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307–312, doi:10.1038/s41586-018-0178-z (2018). - DOI - PMC - PubMed
Butler A, Hoffman P, Smibert P, Papalexi E & Satija R Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nature biotechnology 36, 411–420, doi:10.1038/nbt.4096 (2018). - DOI - PMC - PubMed
Savas P. et al.Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat Med 24, 986–993, doi:10.1038/s41591-018-0078-7 (2018). - DOI - PubMed
Kochenderfer JN et al.Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother 32, 689–702, doi:10.1097/CJI.0b013e3181ac6138 (2009). - DOI - PMC - PubMed
Jerby-Arnon L. et al.A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell 175, 984–997e924, doi:10.1016/j.cell.2018.09.006 (2018). - DOI - PMC - PubMed
Show all 12 references
Publication types
Observational Study Actions
Search in PubMed
Search in MeSH
Add to Search
Research Support, N.I.H., Extramural Actions
Search in PubMed
Search in MeSH
Add to Search
Research Support, Non-U.S. Gov't Actions
Search in PubMed
Search in MeSH
Add to Search
MeSH terms
Adult Actions
Search in PubMed
Search in MeSH
Add to Search
Aged Actions
Search in PubMed
Search in MeSH
Add to Search
CD8-Positive T-Lymphocytes / immunology Actions
Search in PubMed
Search in MeSH
Add to Search
CD8-Positive T-Lymphocytes / pathology Actions
Search in PubMed
Search in MeSH
Add to Search
Cell- and Tissue-Based Therapy / adverse effects* Actions
Search in PubMed
Search in MeSH
Add to Search
Cell-Free Nucleic Acids / blood Actions
Search in PubMed
Search in MeSH
Add to Search
Female Actions
Search in PubMed
Search in MeSH
Add to Search
Humans Actions
Search in PubMed
Search in MeSH
Add to Search
Lymphoma, Large B-Cell, Diffuse / genetics Actions
Search in PubMed
Search in MeSH
Add to Search
Lymphoma, Large B-Cell, Diffuse / immunology Actions
Search in PubMed
Search in MeSH
Add to Search
Lymphoma, Large B-Cell, Diffuse / pathology Actions
Search in PubMed
Search in MeSH
Add to Search
Lymphoma, Large B-Cell, Diffuse / therapy* Actions
Full text links [x] Nature Publishing Group Free PMC article [x] Cite Copy Download .nbib.nbib Format: AMA APA MLA NLM Send To
Clipboard
Email
Save
My Bibliography
Collections
Citation Manager
[x]
NCBI Literature Resources
MeSH PMC Bookshelf Disclaimer
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
Search: Search Advanced Clipboard Save Email Send to
Nature Publishing Group Free PMC article Full text links 
